Vertex Pharmaceuticals (VRTX) Operating Leases (2009 - 2026)

Vertex Pharmaceuticals' Operating Leases history runs 18 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• On a quarterly basis, Operating Leases rose 29.19% year-over-year to $2.0 billion in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 29.19% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, up 13.18% from the prior year.
• Operating Leases improved to $2.0 billion in Q1 2026 per VRTX's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Operating Leases topped out at $2.0 billion in Q1 2026 and bottomed at $354.4 million in Q3 2023.
• The 5-year median for Operating Leases is $382.3 million (2022), against an average of $933.8 million.
• Across the five-year window, Operating Leases slipped 7.6% in 2022 and surged 348.34% in 2024, its largest moves.
• Year by year, Operating Leases stood at $379.5 million in 2022, then grew by 0.58% to $381.7 million in 2023, then jumped by 327.43% to $1.6 billion in 2024, then grew by 13.18% to $1.8 billion in 2025, then increased by 7.58% to $2.0 billion in 2026.
• Per Business Quant, the three latest VRTX Operating Leases figures stand at $2.0 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q3 2025).